ClinicalTrials.gg
CompletedNCT04966325Updated Jan 6, 2022

Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects

An Early Phase 1 interventional study of LC350189 200mg and Placebo in Hyperuricemia, Gout and Qt Interval, Variation in, sponsored by LG Chem. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-01-06.

Sponsored by LG Chem · Early Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2021, 4 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
37
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Hyperuricemia by LG Chem — none open to participants now, none under way, none of them phase 3. Hyperuricemia · LG Chem.

Enrollment
5th of 11
37 · median 37
Started
2021
with 1 other
Phase 1
8 of 11
none open now
Registered
8th of 11
by date

Among the 11 studies in Hyperuricemia by LG Chem, this one is the 5th largest by enrollment, is one of 2 that started in 2021, is one of 8 in phase 1, and was the 8th registered.

Hyperuricemia

240 studies on the registry are indexed under Hyperuricemia; 44 are open to participants now.

Browse Hyperuricemia studies →

Open to participants now

None of the 11 studies in Hyperuricemia by LG Chem is open now. The open studies under Hyperuricemia, anywhere →

Who these studies take

Of the 29 Hyperuricemia studies recruiting now, 8 (28%) set no upper age limit and 13 (45%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Hyperuricemia by LG Chem as a file.
02

Study summary

This is a Phase 1, single-center, randomized, partially double-blind, placebo- and positive controlled, 4-way crossover study to evaluate the effect of a therapeutic and a supratherapeutic dose of LC350189 on the QTcF in healthy male and female subjects.

03

Conditions studied

  • Hyperuricemia
  • Gout
  • Qt Interval, Variation in

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject is 18 to 55 years of age, inclusive, with a (BMI) 18 to 33 kg/m2, inclusive, at screening.
  • The subject is considered by the investigator to be in good general health as determined by medical history, clinical laboratory test results, vital sign measurements, 12-lead results, and physical examination findings at screening.
  • The subject is able to provide written and agrees to comply with all protocol requirements.

Exclusion criteria

Exclusion Criteria:

  • The subject has a history of risk factors for torsades de pointes, including unexplained syncope, known long syndrome, heart failure, myocardial infarction, or angina.
  • The subject has a family history of long QT syndrome, Brugada syndrome, or sudden death.
  • The subject has a resting HR of \<40 bpm or >100 bpm when vital signs are measured at screening or check-in.
  • The subject has history or presence of unstable cardiovascular disease, including myocardial infarction, cardiac arrhythmia, or cerebrovascular disease (eg, cerebrovascular accident/stroke or ).
  • The subject has a history of other acute or chronic cardiovascular disease or coronary revascularization surgery (eg, coronary artery bypass graft, percutaneous transluminal coronary angioplasty).
  • The subject uses a cardiac pacemaker.
  • The subject has a history of any other medical, psychological, or social condition that, in the opinion of the investigator or the medical monitor, would prevent the subject from fully participating in the study, would represent a concern for study compliance, or would constitute a safety concern to the subject.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    Treatment T (Therapeutic dose)

    Single oral dose of 200 mg LC350189 (1 × 200 mg tablet) and 2 × placebo tablets.

    Drug: LC350189 200mg

  • Experimental
    Treatment ST (Supratherapeutic dose)

    Single oral dose of 600 mg LC350189 (3 × 200 mg tablets).

    Drug: LC350189 600mg

  • Placebo comparator
    Treatment P (Placebo)

    Single oral dose of 3 × placebo tablets.

    Drug: Placebo

  • Active comparator
    Treatment M (positive control)

    Single oral dose of moxifloxacin 400 mg (1 × 400 mg tablet; open label)

    Drug: Moxifloxacin 400mg

Interventions

  • Subject will receive an LC350189 200mg as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)

    Also known as: LC350189 (therapeutic dose)

  • DrugPlacebo

    Subject will receive a Placebo as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)

    Also known as: Placebo control

  • Subject will receive a Moxifloxacin 400mg as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)

    Also known as: Positive control

  • Subject will receive an LC350189 600mg as single-dose on Day 1(Period 1) or Day 5(Period 2) or Day 9(Period 3) or Day 13(Period 4)

    Also known as: LC350189 (supratherapeutic dose)

06

What researchers measure

Primary outcomes

  1. The placebo-corrected change from baseline in QTcF

    QTcF will be analyzed using concentration-QT (cQT) modeling

    Time frame: Before dosing (Baseline) through 24 hours after the dose on Day 1 in each treatment period

Secondary outcomes

  1. The placebo-corrected change from baseline in HR (heart rate)

    HR will be evaluated at each postdose time point

    Time frame: Before dosing (Baseline) through 24 hours after the dose on Day 1 in each treatment period

  2. The placebo-corrected change from baseline in PR

    PR will be evaluated at each postdose time point

    Time frame: Before dosing (Baseline) through 24 hours after the dose on Day 1 in each treatment period

  3. The placebo-corrected change from baseline in QRS

    QRS will be evaluated at each postdose time point

    Time frame: Before dosing (Baseline) through 24 hours after the dose on Day 1 in each treatment period

07

Study locations

1 site
  • PPD
    Austin, Texas 78744, United States
08

References and documents

Individual participant data

Plan to share: Undecided — To be determined

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Dec 2021, 2 months.

Of 29 industry-sponsored phase 1 interventional studies under Hyperuricemia, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 9. This study's 2 months is below that.

Counting every sponsor, half of 31 studies reached it within 6 months; a quarter within 1 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2021
First posted
Jul 19, 2021
StartActual
Sep 23, 2021
Primary completionActual
Dec 7, 2021
CompletionActual
Dec 7, 2021
Last update
Jan 6, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04966325
Lead sponsor
LG Chem
Responsible party
Sponsor
First posted
Jul 19, 2021
Start date
Sep 23, 2021
Primary completion
Dec 7, 2021
Completion
Dec 7, 2021
Last update
Jan 6, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tigulixostat

Start the discussion